Hayrettin Tumani

Overview

Best Publications

• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

  Unknown

  1094
  Citations

• Blood GFAP as an emerging biomarker in brain and spinal cord disorders

  Unknown

  944
  Citations

• A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

  Charlotte Teunissen;Axel Petzold;Jeffrey L. Bennett;Frode S. Berven

  886
  Citations

• Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

  Sven Jarius;Klemens Ruprecht;Brigitte Wildemann;Tania Kuempfel

  864
  Citations

• The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

  Niklas Mattsson;Ulf Andreasson;Staffan Persson;Hiroyuki Arai

  452
  Citations

• Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

  Ingo Kleiter;Anna Gahlen;Nadja Borisow;Katrin Fischer

  441
  Citations

• Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

  Markus Otto;Jens Wiltfang;Hayrettin Tumani;Inga Zerr

  430
  Citations

• Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.

  Samir Abu-Rumeileh;Ahmed Abdelhak;Ahmed Abdelhak;Matteo Foschi;Hayrettin Tumani

  421
  Citations

• Consensus guidelines for lumbar puncture in patients with neurological diseases

  Sebastiaan Engelborghs;Ellis Niemantsverdriet;Hanne Struyfs;Kaj Blennow

  366
  Citations

• Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity

  Unknown

  362
  Citations

• Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

  J. Kuhle;G. Disanto;R. Dobson;R. Adiutori

  353
  Citations

• Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients

  Petra Steinacker;Emily Feneberg;Jochen Weishaupt;Johannes Brettschneider

  344
  Citations

• Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis

  P. Rieckmann;M. Albrecht;B. Kitze;T. Weber

  320
  Citations

• Axonal damage markers in cerebrospinal fluid are increased in ALS.

  J Brettschneider;A Petzold;SD Sussmuth;AC Ludolph

  293
  Citations

• Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction

  K. Bechter;H. Reiber;S. Herzog;D. Fuchs

  290
  Citations

• The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

  Martin Stangel;Sten Fredrikson;Edgar Meinl;Axel Petzold;Axel Petzold

  272
  Citations

• TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis

  Petra Steinacker;Corinna Hendrich;Anne D. Sperfeld;Sarah Jesse

  269
  Citations

• Serum GFAP as a biomarker for disease severity in multiple sclerosis

  A. Abdelhak;A. Huss;J. Kassubek;H. Tumani

  267
  Citations

• Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

  Federico Verde;Petra Steinacker;Jochen H Weishaupt;Jan Kassubek

  255
  Citations

• A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking

  Charlotte E. Teunissen;Axel Petzold;Jeffrey L. Bennett;Frode S. Berven

  240
  Citations

• Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions

  Ingo Kleiter;Anna Gahlen;Nadja Borisow;Katrin Fischer

  227
  Citations

• Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

  Ester Cantó;Mar Tintoré;Luisa M Villar;Carme Costa

  211
  Citations

• Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options

  A. C. Ludolph;J. Kassubek;B. G. Landwehrmeyer;E. Mandelkow

  210
  Citations